WATERS CORP /DE/ - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - 8-K - WATERS CORP /DE/	d574853d8k.htm

Exhibit 99.1

For Immediate Release

Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448

Waters Corporation (NYSE: WAT) Reports Second Quarter 2018 Financial Results

•

Sales of $596 million grew 7% as reported and 5% in constant currency

•

Growth across all end markets with strong TA performance

•

Strong growth from China, partially offset by softness in the U.S.

•

GAAP EPS increased 21% to $1.98; non-GAAP EPS increased 11% to $1.95

Milford, Mass., July 24, 2018 - Waters Corporation (NYSE: WAT) today announced second quarter 2018 sales of $596 million, a 7% increase as reported, versus sales of $558 million for the second quarter of 2017. Foreign currency translation increased sales growth by approximately 2% for the quarter.

On a GAAP basis, diluted earnings per share (EPS) for the second quarter increased 21% to $1.98, compared to $1.63 for the second quarter of 2017. On a non-GAAP basis, EPS for the second quarter increased 11% to $1.95, compared to $1.76 for the second quarter of 2017. A description and reconciliation of GAAP to non-GAAP results appear in the table below and can be found on the Company’s website at http://www.waters.com under the caption “Investors.”

On a GAAP basis, net cash provided by operating activities for the second quarter of 2018 decreased to $101 million from $177 million for the second quarter of 2017. On a non-GAAP basis, adjusted free cash flow decreased to $144 million from $159 million for the second quarter of 2017.

For the first half of 2018, the Company’s sales were $1,127 million, up 7% as reported, compared with sales of $1,056 million in the first half of 2017. Foreign currency translation increased sales growth by approximately 4% during the first half of 2018. On a GAAP basis, EPS for the first half of 2018 was up 15% to $3.39, compared to $2.94 for the first half of 2017. On a non-GAAP basis and including adjustments in the attached reconciliation, EPS increased 10% to $3.54 in 2018 as compared to $3.22 for the first half of 2017. On a GAAP basis, net cash provided by operating activities for the first half of 2018 decreased to $277 million from $351 million for the first half of 2017. On a non-GAAP basis, adjusted free cash flow decreased to $304 million from $316 million for the first half of 2017.

Commenting on the Company’s performance, Chris O’Connell, Chairman and Chief Executive Officer, said, “We are pleased that we saw sequential improvement in our second quarter results, highlighted by strong growth in China, our TA product line, and our recurring revenues. In addition, we delivered meaningful operating leverage, which enabled us to achieve double-digit earnings per share growth. Our second quarter results give us confidence in the ongoing growth trajectory of our business.”

Unless otherwise noted, sales growth and decline percentages are presented on an as reported basis and are the same as the sales growth and decline percentages presented on a constant currency basis, as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant currency growth rates found below.

During the second quarter of 2018, sales into the pharmaceutical market grew 6% as reported and 4% in constant currency, sales into the industrial market grew 5% as reported and 3% in constant currency, and sales into the governmental and academic markets grew 16% as reported and 13% in constant currency. During the first half of 2018, sales into the pharmaceutical market grew 7% as reported and 4% in constant currency, sales into the industrial market grew 3% as reported and were flat in constant currency, and sales into the governmental and academic markets grew 13% as reported and 10% in constant currency.

During the second quarter, recurring revenues, which represent the combination of service and precision chemistries revenues, grew 11% as reported and 8% in constant currency, while instrument system sales grew 3% as reported and 2% in constant currency. For the first half of 2018, recurring revenues grew 11% as reported and 7% in constant currency, while instrument system sales grew 2% as reported and were flat in constant currency.

Geographically, sales in Asia during the quarter grew 10% as reported and 8% in constant currency, sales in Europe grew 10% as reported and 5% in constant currency, and sales in the Americas grew 1%, while U.S. sales declined 2%. For the first half of 2018, sales in Asia grew 6% as reported and 4% in constant currency, sales in Europe grew 13% as reported and 4% in constant currency, and sales in the Americas grew 2%, with U.S. sales also growing 2%.

Third Quarter and Fiscal Year 2018 Financial Outlook

Waters Corporation expects third quarter 2018 constant currency sales growth to be in a range of 4% to 6%, and, as of today, currency translation is expected to decrease third quarter sales growth by approximately 1% to 2%. The Company also expects third quarter 2018 non-GAAP earnings per fully diluted share to be in the range of $1.85 to $1.95. Please refer to the table below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the third quarter.

The Company maintains its full-year 2018 guidance for constant currency sales growth in the range of 4% to 6%. As of today, currency translation is expected to increase 2018 sales growth by less than 1%. The Company is revising its guidance for full-year 2018 non-GAAP earnings per fully diluted share to the range of $8.05 to $8.20, from the prior guidance range of $8.10 to $8.30. Please refer to the table below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

Conference Call

Waters Corporation will webcast its second quarter 2018 financial results conference call today, July 24, 2018 at 8:00 a.m. Eastern Time. To listen to the call, please visit www.waters.com, choose “Investors,” and click on the “Live Webcast.” A replay will be available through July 31, 2018 at midnight Eastern Time on the same website by webcast and also by phone at 402-661-5143.

About Waters Corporation

Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for nearly 60 years. With approximately 7,000 employees worldwide, Waters operates directly in 31 countries, including 15 manufacturing facilities, with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with generally accepted accounting principles (GAAP). The Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of Waters Corporation’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting Waters Corporation’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release may contain “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words, “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products

among the Company’s various market sectors from economic, sovereign and political uncertainties; the effect on the Company’s financial results from the United Kingdom voting to exit the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; impact of the newly enacted tax reform legislation in the U.S.; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission, which “Forward-Looking Statements” and “Risk Factors” discussions are incorporated by reference in this release. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release.

Waters Corporation and Subsidiaries

Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)


	Three Months Ended						Six Months Ended
	June 30, 2018			July 1, 2017			June 30, 2018			July 1, 2017
Net sales	$	596,219		$	558,250		$	1,126,889		$	1,056,219
Costs and operating expenses:
Cost of sales		243,135			229,627			464,556			440,722
Selling and administrative expenses		136,645			130,093			267,052			260,766
Research and development expenses		35,644			32,937			70,124			63,689
Litigation provision (settlement)		—			10,018			(1,672	)		10,018
Purchased intangibles amortization		1,602			1,693			3,261			3,422
Acquired in-process research and development		—			—			—			5,000
Operating income		179,193			153,882			323,568			272,602
Other (expense) income*		(1,828	)		(97	)		(1,482	)		52
Interest expense, net		(2,804	)		(5,713	)		(6,976	)		(11,095	)
Income from operations before income taxes		174,561			148,072			315,110			261,559
Provision for income taxes**		18,884			16,250			47,482			24,180
Net income	$	155,677		$	131,822		$	267,628		$	237,379
Net income per basic common share	$	2.00		$	1.65		$	3.42		$	2.97
Weighted-average number of basic common shares		77,833			79,979			78,330			80,029
Net income per diluted common share	$	1.98		$	1.63		$	3.39		$	2.94
Weighted-average number of diluted common shares and equivalents		78,438			80,756			79,041			80,769

The Company adopted new accounting guidance which requires that an employer disaggregate the service cost component from other components of net benefit cost. As a result of the adoption of this standard, the components of net periodic benefit cost other than the service cost component are included in other (expense) income in the consolidated statements of operations and all previous periods have been adjusted accordingly.

The provision for income taxes for the three and six months ended June 30, 2018 includes a $9 million benefit and a $4 million expense, respectively, related to the tax on the change in foreign currency exchange rates on the earnings taxed on December 31, 2017 under the Tax Cuts and Jobs Act. The difference is due to the change from the foreign currency exchange rates required by the U.S. Department of the Treasury on December 31, 2017 to the foreign currency exchange rates on either the date of distribution of assets into the U.S. or the foreign currency exchange rates as of June 30, 2018.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segment, Products & Services, Geography and Markets

Three Months Ended June 30, 2018 and July 1, 2017

(In thousands)


	Three Months Ended				Percent			Current Period Currency		Constant Currency
	June 30, 2018		July 1, 2017		Change			Impact		Growth Rate ^(a)
NET SALES - OPERATING SEGMENT
Waters	$	527,305	$	497,780		6	%	$	10,067		4	%
TA		68,914		60,470		14	%		1,217		12	%

Total	$	596,219	$	558,250		7	%	$	11,284		5	%

NET SALES - PRODUCTS & SERVICES
Instruments	$	289,740	$	282,014		3	%	$	3,349		2	%
Service		207,350		185,412		12	%		5,391		9	%
Chemistry		99,129		90,824		9	%		2,544		6	%

Total Recurring		306,479		276,236		11	%		7,935		8	%

Total	$	596,219	$	558,250		7	%	$	11,284		5	%

NET SALES - GEOGRAPHY
Asia	$	236,905	$	215,703		10	%	$	3,285		8	%
Americas		198,126		196,586		1	%		299		1	%
Europe		161,188		145,961		10	%		7,700		5	%

Total	$	596,219	$	558,250		7	%	$	11,284		5	%

NET SALES - MARKETS
Pharmaceutical	$	338,354	$	319,650		6	%	$	6,228		4	%
Industrial		183,664		174,531		5	%		3,078		3	%
Governmental & Academic		74,201		64,069		16	%		1,978		13	%

Total	$	596,219	$	558,250		7	%	$	11,284		5	%

(a)

The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation’s net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP

Net Sales by Operating Segment, Products & Services, Geography and Markets

Six Months Ended June 30, 2018 and July 1, 2017

(In thousands)


	Six Months Ended				Percent			Current Period Currency		Constant Currency
	June 30, 2018		July 1, 2017		Change			Impact		Growth Rate ^(a)
NET SALES - OPERATING SEGMENT
Waters	$	998,451	$	941,206		6	%	$	32,218		3	%
TA		128,438		115,013		12	%		2,932		9	%

Total	$	1,126,889	$	1,056,219		7	%	$	35,150		3	%

NET SALES - PRODUCTS & SERVICES
Instruments	$	530,147	$	518,407		2	%	$	13,050		—
Service		398,903		359,085		11	%		14,755		7	%
Chemistry		197,839		178,727		11	%		7,345		7	%

Total Recurring		596,742		537,812		11	%		22,100		7	%

Total	$	1,126,889	$	1,056,219		7	%	$	35,150		3	%

NET SALES - GEOGRAPHY
Asia	$	437,185	$	410,809		6	%	$	9,374		4	%
Americas		379,836		371,236		2	%		717		2	%
Europe		309,868		274,174		13	%		25,059		4	%

Total	$	1,126,889	$	1,056,219		7	%	$	35,150		3	%

NET SALES - MARKETS
Pharmaceutical	$	643,682	$	599,460		7	%	$	22,013		4	%
Industrial		345,994		335,834		3	%		9,198		—
Governmental & Academic		137,213		120,925		13	%		3,939		10	%

Total	$	1,126,889	$	1,056,219		7	%	$	35,150		3	%

(a)

Waters Corporation and Subsidiaries

Reconciliation of GAAP to Adjusted Non-GAAP Financials

Quarters and Six Months Ended June 30, 2018 and July 1, 2017

(In thousands, except per share data)


	Selling & Administrative Expenses^(a)			Research & Development Expenses^(a)			Operating Income			Operating Income Percentage			Other (Expense) Income			Income from Operations before Income Taxes			Provision for Income Taxes			Net Income			Diluted Earnings per Share
Quarter Ended June 30, 2018
GAAP	$	138,247		$	35,644		$	179,193			30.1	%	$	(1,828	)	$	174,561		$	18,884		$	155,677		$	1.98
Adjustments:
Purchased intangibles amortization ^(b)		(1,602	)		—			1,602			0.3	%		—			1,602			304			1,298			0.02
Restructuring costs and certain other items ^(c)		(1,189	)		—			1,189			0.2	%		—			1,189			260			929			0.01
Pension termination ^(d)		—			—			—			—			2,165			2,165			520			1,645			0.02
Tax reform ^(h)		—			—			—			—			—			—			8,573			(8,573	)		(0.11	)
Certain income tax items ^(e)		—			—			—			—			—			—			(1,993	)		1,993			0.03

Adjusted Non-GAAP	$	135,456		$	35,644		$	181,984			30.5	%	$	337		$	179,517		$	26,548		$	152,969		$	1.95


Quarter Ended July 1, 2017
GAAP	$	141,804		$	32,937		$	153,882			27.6	%	$	(97	)	$	148,072		$	16,250		$	131,822		$	1.63
Adjustments:
Purchased intangibles amortization ^(b)		(1,693	)		—			1,693			0.3	%		—			1,693			449			1,244			0.02
Restructuring costs and certain other items ^(c)		(1,663	)		—			1,663			0.3	%		—			1,663			735			928			0.01
Litigation provisions ^(f)		(10,018	)		—			10,018			1.8	%					10,018			3,757			6,261			0.08
Certain income tax items ^(e)		—			—			—			—			—			—			(1,972	)		1,972			0.02

Adjusted Non-GAAP	$	128,430		$	32,937		$	167,256			30.0	%	$	(97	)	$	161,446		$	19,219		$	142,227		$	1.76


Six Months Ended June 30, 2018
GAAP	$	268,641		$	70,124		$	323,568			28.7	%	$	(1,482	)	$	315,110		$	47,482		$	267,628		$	3.39
Adjustments:
Purchased intangibles amortization ^(b)		(3,261	)		—			3,261			0.3	%		—			3,261			506			2,755			0.03
Restructuring costs and certain other items ^(c)		(1,757	)		—			1,757			0.2	%		—			1,757			392			1,365			0.02
Pension termination ^(d)		—			—			—			—			2,165			2,165			520			1,645			0.02
Litigation settlement ^(f)		1,672			—			(1,672	)		(0.1	%)		—			(1,672	)		(401	)		(1,271	)		(0.02	)
Stock award modification ^(g)		(1,014	)		—			1,014			0.1	%		—			1,014			243			771			0.01
Tax reform ^(h)		—			—			—			—			—			—			(3,877	)		3,877			0.05
Certain income tax items ^(e)		—			—			—			—			—			—			(2,685	)		2,685			0.03

Adjusted Non-GAAP	$	264,281		$	70,124		$	327,928			29.1	%	$	683		$	321,635		$	42,180		$	279,455		$	3.54


Six Months Ended July 1, 2017
GAAP	$	274,206		$	68,689		$	272,602			25.8	%	$	52		$	261,559		$	24,180		$	237,379		$	2.94
Adjustments:
Purchased intangibles amortization ^(b)		(3,422	)		—			3,422			0.3	%		—			3,422			922			2,500			0.03
Restructuring costs and certain other items ^(c)		(11,011	)		—			11,011			1.0	%		—			11,011			3,794			7,217			0.09
Litigation provisions ^(f)		(10,018	)		—			10,018			0.9	%		—			10,018			3,757			6,261			0.08
Acquired in-process research and development ⁽ⁱ⁾		—			(5,000	)		5,000			0.5	%		—			5,000			962			4,038			0.05
Certain income tax items ^(e)		—			—			—			—			—			—			(2,447	)		2,447			0.03

Adjusted Non-GAAP	$	249,755		$	63,689		$	302,053			28.6	%	$	52		$	291,010		$	31,168		$	259,842		$	3.22

(a)	Selling & administrative expenses include purchased intangibles amortization and litigation provisions. Research & development expenses include acquired in-process research and development.

(b)	The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

(c)

Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations and reduce overhead and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

(d)	The pension expense associated with terminating a frozen defined benefit pension plan was excluded as the Company believes these expenses are not indicative of normal operating costs.

(e)	Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management’s assessment of ongoing examinations or other tax items that are not indicative of the Company’s normal or future income tax expense.

(f)	Litigation provisions and settlement gain were excluded as these costs are isolated, unpredictable and not expected to recur regularly.

(g)	The non-cash expense associated with accelerating the vesting of certain stock awards was excluded as the Company believes these expenses are not indicative of normal operating costs.

(h)

(i)	Acquired In-Process Research and Development was excluded as it relates to milestone payments associated with a licensing arrangement for mass spectrometry that the Company believes is unusual and not indicative of its normal business operations.

Waters Corporation and Subsidiaries

Preliminary Condensed Unclassified Consolidated Balance Sheets

(In thousands and unaudited)


	June 30, 2018		December 31, 2017
Cash, cash equivalents and investments	$	2,248,493	$	3,393,701
Accounts receivable		492,826		533,825
Inventories		299,595		270,294
Property, plant and equipment, net		335,709		349,278
Intangible assets, net		218,175		228,395
Goodwill		357,507		359,819
Other assets		205,439		189,042
Total assets	$	4,157,744	$	5,324,354
Notes payable and debt	$	1,148,450	$	1,997,774
Other liabilities		1,034,200		1,092,792
Total liabilities		2,182,650		3,090,566
Total equity		1,975,094		2,233,788
Total liabilities and equity	$	4,157,744	$	5,324,354

Waters Corporation and Subsidiaries

Preliminary Condensed Consolidated Statements of Cash Flows

Three and Six Months Ended June 30, 2018 and July 1, 2017

(In thousands and unaudited)


	Three Months Ended						Six Months Ended
	June 30, 2018			July 1, 2017			June 30, 2018			July 1, 2017
Cash flows from operating activities:
Net income	$	155,677		$	131,822		$	267,628		$	237,379
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation		9,079			9,139			18,971			17,794
Depreciation and amortization		27,196			29,455			55,836			52,405
Change in operating assets and liabilities, net		(91,236	)		6,635			(65,878	)		43,682

Net cash provided by operating activities		100,716			177,051			276,557			351,260
Cash flows from investing activities:
Additions to property, plant, equipment and software capitalization		(20,839	)		(17,647	)		(36,831	)		(35,358	)
Investment in unaffiliated company		—			—			(3,215	)		(7,000	)
Payments for intellectual property licenses		—			(5,000	)		—			(5,000	)
Net change in investments		331,382			(174,156	)		1,246,428			(246,494	)

Net cash provided by (used in) investing activities		310,543			(196,803	)		1,206,382			(293,852	)
Cash flows from financing activities:
Net change in debt		(99,855	)		44,948			(849,774	)		84,936
Proceeds from stock plans		10,558			19,923			34,845			58,182
Purchases of treasury shares		(270,774	)		(76,661	)		(553,144	)		(165,834	)
Other cash flow from financing activities, net		(4,095	)		1,868			(2,158	)		430

Net cash used in financing activities		(364,166	)		(9,922	)		(1,370,231	)		(22,286	)
Effect of exchange rate changes on cash and cash equivalents		(21,411	)		12,485			(12,823	)		26,502

Increase in cash and cash equivalents		25,682			(17,189	)		99,885			61,624
Cash and cash equivalents at beginning of period		716,522			584,444			642,319			505,631

Cash and cash equivalents at end of period	$	742,204		$	567,255		$	742,204		$	567,255


Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow ^(a)
Net cash provided by operating activities - GAAP	$	100,716		$	177,051		$	276,557		$	351,260
Adjustments:
Additions to property, plant, equipment and software capitalization		(20,839	)		(17,647	)		(36,831	)		(35,358	)
Tax reform payments		46,700			—			46,700			—
Litigation settlement payment		15,400			—			15,400			—
Major facility renovations		1,801			—			1,801			—

Free Cash Flow - Adjusted Non-GAAP	$	143,778		$	159,404		$	303,627		$	315,902

(a)

The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

Waters Corporation and Subsidiaries

Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook

(In thousands, except per share data)


	Three Months Ended September 29, 2018							Twelve Months Ended December 31, 2018
	Range							Range
Projected Sales
Projected constant currency sales growth rate		4	%	-		6	%		4	%	-		6	%
Projected currency impact		(2	%)	-		(1	%)		0	%	-		1	%

Projected sales growth rate as reported		2	%	-		5	%		4	%	-		7	%


Projected Earnings Per Diluted Share	Range							Range
Projected GAAP earnings per diluted share	$	1.81		-	$	1.91		$	7.81		-	$	7.96
Adjustments:
Purchased intangibles amortization	$	0.02		-	$	0.02		$	0.07		-	$	0.07
Restructuring costs and certain other items	$	—		-	$	—		$	0.02		-	$	0.02
Pension termination	$	0.01		-	$	0.01		$	0.04		-	$	0.04
Litigation provision	$	—		-	$	—		$	(0.02	)	-	$	(0.02	)
Stock award modification	$	—		-	$	—		$	0.01		-	$	0.01
Tax reform	$	—		-	$	—		$	0.05		-	$	0.05
Certain income tax items	$	0.01		-	$	0.01		$	0.07		-	$	0.07

Projected adjusted non-GAAP earnings per diluted share	$	1.85		-	$	1.95		$	8.05		-	$	8.20

Constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency as well as an assessment of market conditions as of today and may differ significantly from actual results.

These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

WATERS CORP /DE/ - FORM 8-K - EX-99.1 - July 24, 2018

Attached files

WATERS CORP /DE/ Reports